Tate & Lyle (TATE) Business Combination (Q&A) summary

Deal rationale and strategic fit

• Tate & Lyle will acquire CP Kelco for $1.8 billion, creating a global leader in specialty food and beverage solutions and accelerating transformation toward growth-focused, health-driven markets.

• The combination strengthens platforms in mouthfeel, sweetening, and fortification, expanding offerings in a $19 billion, 6% CAGR specialty ingredients market and core categories like beverage, dairy, bakery, and snacks.

• Addresses key consumer trends such as clean-label, plant-based, and added fibre, enhancing customer value and supporting healthier, more sustainable food solutions.

• Opens new adjacencies in personal care and household by leveraging nature-based ingredients and expands presence in high-growth regions.

• Both companies share a commitment to science, sustainability, and positive social impact, with a strong cultural and strategic fit.

Financial terms and conditions

• Total consideration is $1.8 billion: $1.15 billion in cash, 75 million new Tate & Lyle shares to Huber (valued at ~$645 million), and up to 10 million deferred shares based on performance two years post-completion.

• Headline consideration represents 10x CP Kelco's adjusted EBITDA for 2023, including run-rate cost synergies.

• Cash portion funded by new and existing debt facilities, including a $600 million bridge facility.

• Huber will become a long-term shareholder (~16%) and can appoint up to two non-executive directors to Tate & Lyle’s board.

• No profit forecast or guarantee of future performance; forward-looking statements subject to uncertainty.

Synergies and expected cost savings

• Targeted run-rate cost synergies of at least $50 million by the end of the second full financial year post-completion, with 50–60% from procurement, operations, and SG&A.

• Revenue synergies targeted at up to 10% of CP Kelco’s revenue over the medium term, driven by combined solution selling and expanded product offerings.

• Cost to deliver synergies estimated at $75 million.

• Enhanced EBITDA margin anticipated through cost synergies, revenue synergies, and business recovery, with margins expected to recover to above 20% over the longer term.

• Cost synergies to be realized in the first two years post-acquisition.